Meta-analysis of clinical data using human meiotic genes identifies a novel cohort of highly restricted cancer-specific marker genes

Autor: Ahmed Almatrafi, Rebecca Anderson, Mikhlid Almutairi, Ibrahim Aldeailej, Lee Larcombe, Ramsay J. McFarlane, Nicholas Stuart, Julia Feichtinger, Jane A. Wakeman, Naif O. Alsiwiehri, Keith Griffiths
Předmět:
Zdroj: Europe PubMed Central
Oncotarget
Popis: Julia Feichtinger 1 , Ibrahim Aldeailej 1,* , Rebecca Anderson 1,* , Mikhlid Almutairi 1 , Ahmed Almatrafi 1 , Naif Alsiwiehri 1 , Keith Griffiths 2 , Nicholas Stuart 1,3,5 , Jane A. Wakeman 1 , Lee Larcombe 4 and Ramsay J. McFarlane 1,5 1 North West Cancer Research Fund Institute, Bangor University, Bangor, LL57 2UW,UK 2 Therapies and Health Sciences, Betsi Cadwaladr University Health Board, Bangor, LL57 2UW,UK 3 Medical Sciences, Bangor University, Bangor, LL57 2UW,UK 4 Bioinformatics Group, Cranfield Health, Cranfield University, Beds, MK43 0AL,UK 5 NISCHR Cancer Genetics Biomedical Research Unit * These authors made an equal contribution Received: July 26, 2012; Accepted: August 02, 2012; Published: August 13, 2012; Keywords: cancer biomarkers, cancer testes antigens, oncogenes, meiosis, PRDM9, cohesins drug targets Correspondence: Jane A. Wakeman/Ramsay J. McFarlane, email: // // Abstract Identifying cancer-specific biomarkers represents an ongoing challenge to the development of novel cancer diagnostic, prognostic and therapeutic strategies. Cancer/testis (CT) genes are an important gene family with expression tightly restricted to the testis in normal individuals but which can also be activated in cancers. Here we develop a pipeline to identify new CT genes. We analysed and validated expression profiles of human meiotic genes in normal and cancerous tissue followed by meta-analyses of clinical data sets from a range of tumour types resulting in the identification of a large cohort of highly specific cancer biomarker genes, including the recombination hot spot activator PRDM9 and the meiotic cohesin genes SMC1beta and RAD21L . These genes not only provide excellent cancer biomarkers for diagnostics and prognostics, but may serve as oncogenes and have excellent drug targeting potential.
Databáze: OpenAIRE